.

Make Better Decisions

  • Analyze global market entry opportunities
  • Uncover prior art in expired and abandoned patents
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Queensland Health
Accenture
Novartis
Cantor Fitzgerald
Fuji
Argus Health
Cerilliant
Healthtrust
Baxter
Moodys

Generated: December 12, 2017

DrugPatentWatch Database Preview

Perampanel - Generic Drug Details

« Back to Dashboard

What are the generic drug sources for perampanel and what is the scope of perampanel patent protection?

Perampanel
is the generic ingredient in one branded drug marketed by Eisai Inc and is included in two NDAs. There are two patents protecting this compound and one Paragraph IV challenge. Additional information is available in the individual branded drug profile pages.

Perampanel has ninety-nine patent family members in thirty-two countries and sixteen supplementary protection certificates in twelve countries.

There are five drug master file entries for perampanel. One supplier is listed for this compound.

Pharmacology for perampanel

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Patent Submitted Product Substance Delist Req. Exclusivity Expiration
Eisai IncFYCOMPAperampanelTABLET;ORAL202834-001Oct 22, 2012RXYesNo► Subscribe► Subscribe► SubscribeY► Subscribe
Eisai IncFYCOMPAperampanelTABLET;ORAL202834-003Oct 22, 2012RXYesNo► Subscribe► Subscribe► Subscribe► Subscribe
Eisai IncFYCOMPAperampanelTABLET;ORAL202834-005Oct 22, 2012RXYesNo► Subscribe► Subscribe► Subscribe► Subscribe
Eisai IncFYCOMPAperampanelSUSPENSION;ORAL208277-001Apr 29, 2016RXYesYes► Subscribe► Subscribe► SubscribeYY► Subscribe
Eisai IncFYCOMPAperampanelTABLET;ORAL202834-004Oct 22, 2012RXYesNo► Subscribe► Subscribe► Subscribe► Subscribe
Eisai IncFYCOMPAperampanelTABLET;ORAL202834-004Oct 22, 2012RXYesNo► Subscribe► Subscribe► Subscribe► Subscribe
Eisai IncFYCOMPAperampanelTABLET;ORAL202834-002Oct 22, 2012RXYesNo► Subscribe► Subscribe► SubscribeYY► Subscribe
Eisai IncFYCOMPAperampanelTABLET;ORAL202834-003Oct 22, 2012RXYesNo► Subscribe► Subscribe► Subscribe► Subscribe
Eisai IncFYCOMPAperampanelTABLET;ORAL202834-002Oct 22, 2012RXYesNo► Subscribe► Subscribe► SubscribeY► Subscribe
Eisai IncFYCOMPAperampanelTABLET;ORAL202834-004Oct 22, 2012RXYesNo► Subscribe► Subscribe► SubscribeY► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Generic Ingredient: perampanel

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,304,548Method for producing 1, 2-dihydropyridine-2-one compound► Subscribe
7,939,5491,2-dihydropyridine compounds, manufacturing method thereof and use thereof► Subscribe
7,563,8111,2-dihydropyridine compounds, manufacturing method thereof and use thereof► Subscribe
9,045,426Method for producing 1,2-dihydropyridine-2-one compound► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Ingredient: perampanel

Country Document Number Estimated Expiration
China1245386► Subscribe
JapanWO2006004107► Subscribe
New Zealand522773► Subscribe
Slovenia1772450► Subscribe
Japan5068069► Subscribe
European Patent Office2586771► Subscribe
Brazil0111596► Subscribe
Taiwan200815402► Subscribe
Malaysia148809► Subscribe
World Intellectual Property Organization (WIPO)2006004107► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Tradename: PERAMPANEL

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
C0074France► SubscribePRODUCT NAME: PERAMPANEL, SEL DE CELUI-CI OU HYDRATE DE CELUI-CI; REGISTRATION NO/DATE: EU/1/12/776/001 20120723
00566Netherlands► SubscribePRODUCT NAME: PERAMPANEL, EEN ZOUT OF EEN HYDRAAT DAARVAN; REGISTRATION NO/DATE: EU/1/12/776/001 .... 016 20120723
1300396/01Switzerland► SubscribePRODUCT NAME: PERAMPANEL; REGISTRATION NO/DATE: SWISSMEDIC 62440 14.12.2012
2012 00052Denmark► Subscribe
3 5-2013Slovakia► SubscribePRODUCT NAME: PERAMPANEL; NAT. REGISTRATION NO/DATE: EU/1/12/776/001 - EU/1/12/776/016 20120723; FIRST REGISTRATION: EU EU/1/12/776/001 - EU/1 /12/776/016 20120723
2013017,C1764361Lithuania► SubscribePRODUCT NAME: PERAMPANELUM; REGISTRATION NO/DATE: EU/1/12/776/001 - EU/1/12/776/016, 2012 07 23 EU/1/12/776/017 - EU1/12/776/023 20121029
0566Netherlands► SubscribePRODUCT NAME: PERAMPANEL, EEN ZOUT OF EEN HYDRAAT DAARVAN; REGISTRATION NO/DATE: EU/1/12/776/001 .... 016 20120723
00565Netherlands► SubscribePRODUCT NAME: PERAMPANEL, EEN ZOUT OF EEN HYDRAAT ERVAN; REGISTRATION NO/DATE: EU/1/12/776/001 .....016 20120723
C/GB12/057United Kingdom► SubscribePRODUCT NAME: PERAMPANEL, OPTIONALLY IN THE FORM OF A SALT OR HYDRATE; REGISTERED: UK EU/1/12/776/001- 016 20120723
113Luxembourg► SubscribePRODUCT NAME: PERAMPANEL ET SES DERIVES PHARMACEUTIQUEMENT ACCEPTABLES (FYCOMPA)
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Cerilliant
Fuji
Queensland Health
McKesson
Johnson and Johnson
AstraZeneca
US Army
Federal Trade Commission
Cipla
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot